ArticleScientific reports2026
Influence of endogenous estrogen exposure on the development of hypertension in a cohort study using multistate model analysis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The protective effect of endogenous estrogen exposure (EEE) duration on hypertension (HTN) risk was shown previously. This study aimed to investigate the effect of EEE on the transitions of different blood pressure (BP) states using a multi-state Markov model. At the study initiation, 2911 normotensive women aged ≥ 20 years were eligible. The Multi-state Markov model, a robust statistical tool, was used to explore the transition probability of various HTN stages, including (I) normotensive to pre-HTN, (II) normotensive to HTN, and (III) pre-HTN to HTN. At the end of the follow-up of 2911normotensive women, 1544 (53%) and 78 (2%) developed pre-HTN and HTN, respectively. The protective effect of EEE duration was observed in all HTN transitions. The most protective effect was observed in transition II [hazard ratio: 0.53; 95% confidence interval (CI): 0.42, 0.66]. Meanwhile, this protective effect in transitions I and III was 11% (95% CI: 0.82, 0.97) and 21% (95% CI: 0.68, 0.91), respectively. Age and family history of HTN were confounding variables that significantly increased the risk of BP progression across all three transitions. An elevated body mass index and a history of diabetes mellitus were found to increase the risk of HTN progression in transition I and II, respectively. The findings indicate that a prolonged duration of EEE was associated with a protective effect against HTN risk across all HTN progression transitions. Furthermore, individuals with shorter EEE durations may warrant closer monitoring due to their elevated risk of transitioning from normotensive to hypertensive states.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.